Ewald Van Den Bremer

Title: Ewald Van Den Bremer: Innovator in Antibody Technology

Introduction

Ewald Van Den Bremer is a notable inventor based in Eindhoven, Netherlands. He has made significant contributions to the field of antibody technology, particularly in the modulation of complement-dependent cytotoxicity. His work has implications for therapeutic applications in various diseases.

Latest Patents

Ewald holds a patent titled "Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains." This patent describes antibody variants that possess either decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to modifications at the C-terminus of their heavy chains. The patent also outlines methods for generating such antibodies, along with nucleotide constructs and host cells suitable for their production. He has 1 patent to his name.

Career Highlights

Ewald is currently associated with Genmab A/S, a leading biotechnology company focused on the development of differentiated antibody therapeutics for the treatment of cancer. His work at Genmab has positioned him as a key player in advancing antibody-based therapies.

Collaborations

Ewald has collaborated with notable colleagues such as Paul Parren and Patrick Van Berkel. These collaborations have further enriched his research and development efforts in the field of antibody technology.

Conclusion

Ewald Van Den Bremer's innovative work in antibody technology exemplifies the impact of scientific research on therapeutic advancements. His contributions continue to shape the future of medical treatments.